Pharmafile Logo

Tysabri

- PMLiVE

Tecfidera successor’s side-effect profile boosts Biogen

But analysts unconvinced that patients will switch

- PMLiVE

Biogen grows in Q2, but Spinraza performance a concern

Company banking on pipeline readouts and Tecfidra defence

The role of brain health in treating MS

Blue Latitude Health speaks to Professor Gavin Giovannoni, key opinion leader and Chair of Neurology, Barts and The London School of Medicine and Dentistry, about his theories on brain health,...

Blue Latitude Health

Diagnosing MS: are we getting it right?

Multi-award-winning patient advocate, Trishna Bharadia, walks through the complications involved with an MS diagnosis, including the challenges for healthcare systems and a handful of insightful patient stories.

Blue Latitude Health

- PMLiVE

Biogen bounces back with Spinraza early treatment data

Takes battle to Novartis in youngest patients

Empowering the MS patient through shared decision making

Patient advocate Trishna Bharadia explains why shared decision making is crucial for ensuring multiple sclerosis patients feel heard and empowered

Blue Latitude Health

My MS journey: one patient’s search for innovation

David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients.

Blue Latitude Health

- PMLiVE

Biogen trumpets safety data for Tecfidera follow-up

Much riding on blockbuster's successor

Teva Pharma logo

US states sue generic firms over ‘inflated’ prices

Companies accused of “multi-billion dollar fraud" and conspiracy

- PMLiVE

Roche and NHS England hail pricing deal on MS drug Ocrevus

Another pricing deal on high cost medicine

Biogen Idec building

Biogen’s tofersen shows promise in slowing down ALS

Hope for subset of patients with wasting disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links